Zobrazeno 1 - 10
of 188
pro vyhledávání: '"J.-Matthias Graf von der Schulenburg"'
Autor:
Johannes Boettcher, Bonnie Filter, Jonas Denecke, Amra Hot, Anne Daubmann, Antonia Zapf, Karl Wegscheider, Jan Zeidler, J.-Matthias Graf von der Schulenburg, Monika Bullinger, Miriam Rassenhofer, Michael Schulte-Markwort, Silke Wiegand-Grefe
Publikováno v:
BMC Family Practice, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background Families of children with rare diseases (i.e., not more than 5 out of 10,000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and its siblings. Although families car
Externí odkaz:
https://doaj.org/article/e40efbedc6d7412e871242ec4db6b92a
Autor:
Svenja Litzkendorf, Martin Frank, Ana Babac, Daniel Rosenfeldt, Franziska Schauer, Tobias Hartz, J.-Matthias Graf von der Schulenburg
Publikováno v:
BMC Public Health, Vol 20, Iss 1, Pp 1-14 (2020)
Abstract Background Finding reliable information on one of more than 7000 rare diseases is a major challenge for those affected. Since rare diseases are defined only by the prevalence criterion, a multitude of heterogeneous diseases are included. Com
Externí odkaz:
https://doaj.org/article/20f799d1b02744f896a286975b6c5e8b
Publikováno v:
Health Economics Review, Vol 9, Iss 1, Pp 1-17 (2019)
Abstract Background Since the implementation of the Regulation on Patient Integration (2003), the Act on the Reorganization of the Pharmaceutical Market (2011), and the Patient Rights Law (2013), the inclusion of patient perspectives has been further
Externí odkaz:
https://doaj.org/article/a02c93154c8f4c40afc9cbbe9ba45d14
Autor:
Ana Babac, Verena von Friedrichs, Svenja Litzkendorf, Jan Zeidler, Kathrin Damm, J.-Matthias Graf von der Schulenburg
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 19, Iss 1, Pp 1-17 (2019)
Abstract Background Many European countries have recently implemented national rare disease plans. Although the network is strengthening, especially on the macro and meso levels, patients still go a long way through healthcare systems, with many heal
Externí odkaz:
https://doaj.org/article/6b3ba6c61d6844ed9cedb654924d13e4
Autor:
Thomas R. Staab, Miriam Walter, Sonja Mariotti Nesurini, Charalabos-Markos Dintsios, J.-Matthias Graf von der Schulenburg, Volker E. Amelung, Jörg Ruof
Publikováno v:
Health Economics Review, Vol 8, Iss 1, Pp 1-11 (2018)
Abstract Background According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of new medicines as a basis for subsequent price negotiations. Pharmaceutical companies may withdraw their medications from th
Externí odkaz:
https://doaj.org/article/b0233d39cbbf4519bd29290918586e0e
Publikováno v:
Health Economics Review, Vol 11, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/23ae21cd8d4e4743974b6fb2c091e3a2
Publikováno v:
Health and Quality of Life Outcomes, Vol 15, Iss 1, Pp 1-13 (2017)
Abstract Background The EuroQol Group has extended the severity levels of the EQ-5D from three to five (EQ-5D-5L). There are valuation studies worldwide planned in order to convert the EQ-5D-5L health states into a single preference-based summary sco
Externí odkaz:
https://doaj.org/article/1683089d79bd4be6b3d14eba081ad42c
Insurance today is a global economic colossus and a fixture in the developed countries of the world. Dependant upon a considerable dose of moral exhortation and enlightened appeal, the insurance industry has become a pervasive agent of social and eco
Publikováno v:
The European Journal of Health Economics. 24:803-816
This paper examines dividend policy issues in the European pharmaceutical industry. This sector is of particular interest because of the high research and development expenditures and the associated risks characterizing the business models of many fi
Autor:
Michael Thomas, Manfred Dietel, Silke Zaun, Monika Serke, Christian Schumann, Joerg Mezger, J.-Matthias Graf von der Schulenburg, Juergen R. Fischer, Wilfried Ernst Erich Eberhardt, Peter Schirmacher, Wolfgang Schuette
EPI-14-1149 . EGFR mutation type by tissue source tested
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d831f9da206095ed155297cf9641c7e
https://doi.org/10.1158/1055-9965.22438029
https://doi.org/10.1158/1055-9965.22438029